Skip to main content
SpringerLink
Log in

Intravesical chemotherapy in the United States

An overview

  • Intravesical Chemotherapy, United States
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Intravesical chemotherapy has been widely employed in this country as part of the treatment strategy for clinically localized bladder cancer. Although surgery remains the principal therapeutic modality, intravesical agents are increasingly being considered as adjuncts and as salvage or prophylactic therapy for polychronotopic superficial disease. Instillation treatment is first-line therapy for diffuse in situ carcinoma.

Several compounds have been subjected to intravesical trials in this country, but thio-TEPA has been most extensively studied. More recently mitomycin C and Adriamycin have been utilized following encouraging preliminary reports from abroad. BCG, a biologic agent, has also stimulated interest and current trials. Phase I–II studies with intravesical interferon have been initiated.

While the potential role for intravesical therapy is becoming clear, additional trials to test new agents, compare current agents, and refine dose, concentration, volume, and contact time are indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abrams PH, Choa RG, Gaches CGC, Ashken MH, Green NA (1981) A controlled trial of single-dose intravesical Adriamycin in superficial bladder tumours. Br J Urol 53: 585

    Google Scholar 

  2. Asahi T, Matsumura Y, Tanahashi T, et al. (1980) The effects of intravesical instillation of thiotepa on the recurrence rate of bladder tumors. Acta Med Okayama 34: 43

    Google Scholar 

  3. Banks MD, Pontes JE, Izbicki RM, Pierce JM Jr (1977) Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol 118: 757

    Google Scholar 

  4. Bracken RB, Johnson DE, Rodriquez L, Samuels ML, Ayala A (1977) Treatment of multiple superficial tumors of bladder with intravesical bleomycin. Urology 9: 161

    Google Scholar 

  5. Bracken RB, Johnson DE, von Eschenbach AC et al. (1980) Role of intravesical mitomycin C in management of superficial bladder tumors. Urology 16: 11

    Google Scholar 

  6. Brosman SA (1982) Experience with Bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128: 27

    Google Scholar 

  7. Burnand KG, Boyd PJR, Mayo ME, Shuttleworth KED, Lloyd-Davies RW (1976) Single-dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol 48: 55

    Google Scholar 

  8. Byar D, Blackard C, and The Veterans Administration Cooperative Urological Research Group (1977) Comparisons of placebo pyridoxine and topical thiotepa in preventing recurrence of stage I Bladder cancer. Urology 10: 556

    Google Scholar 

  9. Camuzzi F, Bondus M, Lockhart J, Politano V (1980) Mitomycin C in the treatment of superficial bladder cancer. Proc Am Urol Assoc Abstract 120

  10. DeFuria MD, Bracken RB, Johnson DE, et al. (1980) Phase I–II study of Mitomycin C topical therapy for low-grade, low-stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep 64: 225

    Google Scholar 

  11. Drew JE, Marshall VF (1968) The effects of topical thiotepa on the recurrence rate of superficial bladder cancers. J Urol 99: 740

    Google Scholar 

  12. Edsmyr F, Berlin T, Boman J et al. (1980) Intravescial therapy with Adriamycin in patients with superficial bladder tumors Eur Urol 6: 132

    Google Scholar 

  13. England HR, Flynn JT, Paris AMI, Blandy JP (1981) Early multiple dose adjuvant thiotepa in the control of multiple and rapid T1 tumor neogenesis. Br J Urol 53: 588

    Google Scholar 

  14. Esquivel EL Jr, Mackenzie AR, Whitmore WF Jr (1965) Treatment of bladder tumors by instillation of thiotepa, actinomycin D or 5-fluorouracil. Invest Urol 2: 381

    Google Scholar 

  15. Garnick MB, Schade D, Israel M, Richie JP (1982) Clinical pharmacologic evaluation of intravesical Adriamycin for recurrent superficial bladder carcinoma. Proc Am Urol Assoc Abstract 445

  16. Gavrell GJ, Lewis RW, Meehan WL, Leblanc GA (1978) Intravesical thiotepa in the immediate post-operative period in patients with recurrent transitional cell carcinoma of the bladder. J Urol 120: 410

    Google Scholar 

  17. Hall RR, Herring DW, Gibb I, Heath AB (1981) Prophylactic oral methotrexate therapy for multiple superficial bladder carcinoma. Br J Urol 53: 582

    Google Scholar 

  18. Herr HW, Pinsky CM, Whitmore WF Jr, Oettgen HF, Melamed MR (1983) Effect of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. Cancer 51: 1323

    Google Scholar 

  19. Hollister D, Coleman M (1980) Hematologic effects of intravesical thiotepa therapy for carcinoma of the bladder. J Urol 125: 307

    Google Scholar 

  20. Homonnai TZ, Paz G, Servadio C (1982) Sterilization following instillation of thiotepa into the urinary bladder. Br J Urol 54: 60

    Google Scholar 

  21. Ikic D, Maricic Z, Oresic V, et al. (1981) Application of human leucocyte interferon in patients with urinary bladder papillomatosis, treast cancer, and melanoma. Lancet I: 1022

    Google Scholar 

  22. Jakse G, Marburger H (1982) Adriamycin therapy for carcinoma in situ of the urinary bladder. Proc Am Urol Assoc Abstract 446

  23. Jones HC, Swinney J (1961) Thiotepa in the treatment of tumours of the bladder. Lancet II: 615

    Google Scholar 

  24. Koontz WW Jr, Prout GR Jr, Smith W, Frable WJ, Minnis JE (1981) The use of intravesical thiotepa in the management of non invasive carcinoma of the bladder. J Urol 125: 307

    Google Scholar 

  25. Lamm DL, Thor DE Winters WD, Stogdill VD, Radwin HM (1981) BCG immunotherapy of bladder cancer. Cancer 48: 82

    Google Scholar 

  26. Mishina T, Oda K, Murata S et al. (1975) Mitomycin C bladder instillation therapy for bladder tumors. J Urol 114: 217

    Google Scholar 

  27. Mobley WC, Loening SA, Narayana AS, Culp DA (1982) The use of intravesical cisplatinum and mitomycin C for recurrent transitional cell carcinoma of the bladder refractory to intravesical thio-tepa. Proc Am Urol Assoc Abstract 495

  28. Morales A, Ersil A (1979) Prophylaxis of recurrent bladder cancer with bacillus Calmette-Guerin: In: Johnson DE, Samuels ML (eds), Cancer of the genitourinary tract. Raven Press, New York, pp 121–132

    Google Scholar 

  29. Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180

    CAS  PubMed  Google Scholar 

  30. Morales A, Pang ADS, Ottenhof PC (1982) Treatment of residual noninfiltrating bladder cancer with Bacillus Calmette-Guerin (BCG). Proc Am Urol Assoc Abstract 587

  31. Nieh PT, Daly JJ, Heaney JA, Heney NM, Prout GR Jr (1978) The effect of intravesical thio-tepa on normal and tumor urothelium. J Urol 119: 59

    Google Scholar 

  32. Nissenkorn I (1981) Side effects associated with intravesical mitomycin C. J Urol 126: 596

    Google Scholar 

  33. Northern California Oncology Group: Protocol 4B-82-1

  34. Oravisto KJ (1972) Optimal intravesical dosage of thiotepa in the prophylaxis of recurrent bladder papillomatosis. Scand J Urol Nephrol 6: 26

    Google Scholar 

  35. Osaki Y (1977) Bladder instillation of Adriamycin in the treatment of bladder tumors. 1: Clinical results. Jpn J Urol 68: 934

    Google Scholar 

  36. Pavone-Macaluso M, Ingargiola GB (1980) Local chemotherapy in bladder cancer treatment. Oncology [Suppl 1] 37: 71

    Google Scholar 

  37. Prout GR Jr, Griffin PP, Nocks BN, DeFuria MD, Daly JJ (1982a) Intravesical therapy of low-stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients. J Urol 127: 1096

    Google Scholar 

  38. Prout GR Jr, Koontz WW Jr, Cutler S, et al. (1982a) A chemopreventive trial of cis-retinoic acid in patients with recurrent bladder carcinoma. Proc Am Urol Assoc Abstract 96

  39. Smith PH (1981) Chemotherapy of bladder cancer: a review. Cancer Treat Rep [Suppl 1] 65: 165

    Google Scholar 

  40. Veenema RJ, Dean AL Jr, Roberts M, et al. (1962) Bladder carcinoma treated by direct instillation of thio-tepa. J Urol 88: 60

    Google Scholar 

  41. Veenema RJ, Dean AL Jr, Uson AC, Roberts M, Longo F (1969) Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. J Urol 101: 711

    Google Scholar 

  42. Veenema RJ, Romas NA, and Fingerhut B (1974) Chemotherapy for bladder cancer. Urology 3: 135

    Google Scholar 

  43. Wescott JW (1966) The prophylactic use of thio-tepa in transitional cell carcinoma of the bladder. J Urol 96: 913

    Google Scholar 

  44. Zincke H, Utz DC, Taylor WF, Meyers RP, Leary FJ (1983) Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective randomized, double-blind, controlled trial. J Urol 129: 505

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 909 Hyde St., Suite 222, 94109, San Francisco, CA, USA

    Joseph T. Spaulding

Authors
  1. Joseph T. Spaulding
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spaulding, J.T. Intravesical chemotherapy in the United States. Cancer Chemother. Pharmacol. 11 (Suppl 1), S5–S8 (1983). https://doi.org/10.1007/BF00256708

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00256708

Keywords

Search

Navigation